anlotinib + epirubicin

**Anlotinib + epirubicin** is a combination therapy of two small molecule drugs used investigationally for the first-line treatment of advanced or metastatic soft tissue sarcoma (STS)[1][2][3][5][7].\n- **Anlotinib** is a selective multi-kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and c-Kit, thereby inhibiting tumor angiogenesis and cell proliferation[1][7].\n- **Epirubicin** is an anthracycline chemotherapeutic agent that intercalates into DNA and inhibits topoisomerase II, leading to the inhibition of DNA replication and repair, and induces cell death.\nThe combination has shown synergistic activity both in patient-derived xenograft (PDX) models and in patients, with improved efficacy and a tolerable safety profile relative to historic controls[1][2][3][5][7]. The primary indication studied is unresectable locally advanced or metastatic soft tissue sarcoma, with phase II clinical trial evidence suggesting improved progression-free survival over chemotherapy alone[1][2][3][5].

Other names

anlotinib plus epirubicinanlotinib and epirubicin